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Muscle and adipose tissue 
morphology, insulin sensitivity and 
beta-cell function in diabetic and 
nondiabetic obese patients: effects 
of bariatric surgery
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Obesity is characterized by insulin-resistance (IR), enhanced lipolysis, and ectopic, inflamed fat. We 
related the histology of subcutaneous (SAT), visceral fat (VAT), and skeletal muscle to the metabolic 
abnormalities, and tested their mutual changes after bariatric surgery in type 2 diabetic (T2D) and 
weight-matched non-diabetic (ND) patients. We measured IR (insulin clamp), lipolysis (2H5-glycerol 
infusion), ß-cell glucose-sensitivity (ß-GS, mathematical modeling), and VAT, SAT, and rectus abdominis 
histology (light and electron microscopy). Presurgery, SAT and VAT showed signs of fibrosis/necrosis, 
small mitochondria, free interstitial lipids, thickened capillary basement membrane. Compared to ND, 
T2D had impaired ß-GS, intracapillary neutrophils and higher intramyocellular fat, adipocyte area in 
VAT, crown-like structures (CLS) in VAT and SAT with rare structures (cyst-like) ~10-fold larger than 
CLS. Fat expansion was associated with enhanced lipolysis and IR. VAT histology and intramyocellular 
fat were related to impaired ß-GS. Postsurgery, IR and lipolysis improved in all, ß-GS improved in 
T2D. Muscle fat infiltration was reduced, adipocytes were smaller and richer in mitochondria, and 
CLS density in SAT was reduced. In conclusion, IR improves proportionally to weight loss but remains 
subnormal, whilst SAT and muscle changes disappear. In T2D postsurgery, some VAT pathology persists 
and beta-cell dysfunction improves but is not normalized.
Obesity is associated with chronic low-grade inflammation in adipose tissue, which accompanies, and may con-
tribute to the development of, insulin resistance and type 2 diabetes (T2D)1. In obese mice and humans, as hyper-
trophic adipocytes become insulin resistant, their lipolytic activity is accelerated; as a consequence, nonesterified 
fatty acids (NEFA) flux is partially shunted away from adipose tissue toward ectopic depots (in liver, muscle, and 
other organs). These changes in the metabolic phenotype are accompanied by an increased expression and release 
of inflammatory cytokines2, which further stimulate lipolysis. In addition, expanded adipose depots are infiltrated 
by macrophages and T cells, expressing high levels of inflammatory cytokines3. Macrophage infiltration is pos-
itively related to the size of adipocytes and coincides with the appearance of insulin resistance as macrophages 
alter the levels of insulin signalling molecules and GLUT4 and inhibit insulin action4.
In obese humans, adipocyte death is an accelerated phenomenon5. In both lean and obese mice over 90% of 
macrophages infiltrating the adipose tissue are found around dead adipocytes, forming characteristic structures 
termed ‘crown-like structures’ (CLS). Density of CLS is positively related to adipocyte size, independent of obesity 
status6. Adipose tissue from humans shows similar features6. Macrophages penetrate adipose tissue to remove 
remnants of dead adipocytes; due to the small size of macrophages and the time required for the dead adipocyte 
removal process, chronic low-grade inflammation is induced, similar to that observed in foreign body reactions7, 8. 
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In mice, for adipocytes of the same size CLS density is higher in visceral adipose tissue (VAT), suggesting that 
adipocytes at this location are more fragile and reach a critical size that triggers death, termed the ‘critical death 
size’, earlier than adipocytes in subcutaneous adipose tissue (SAT)9.
These observations made in animal models and humans have led to the concept that the insulin resistance of 
obesity is a disease of the adipose tissue, which propagates to muscle (intramuscular lipid accumulation)10 and 
liver (steatosis)11. Implicit in this construct is that weight loss should cause regression of both the histologic and 
physiological abnormalities of the obese state. Despite the insulin resistance and low-grade inflammation, how-
ever, many obese subjects do not develop T2D, the emergence of which is marked and anteceded by a variable 
degree of beta-cell failure in both obese and lean individuals12. Whether T2D is associated with adipose tissue 
changes distinct from those of simple obesity is not clear given the frequent co-existence of the two conditions.
The first aim of the present study was to provide an integrated picture of both the histological (fat and muscle) 
and physiological (insulin resistance, lipolysis, subclinical inflammation, beta-cell function) abnormalities of 
obesity – and their relationships – in groups of non-diabetic or T2D obese individuals. To this end, we carried 
out morphologic (morphometry, immunohistochemistry, and electron microscopy) analyses of VAT, SAT, and 
skeletal muscle, measured insulin resistance (by the euglycaemic insulin clamp technique), beta-cell function 
(from a mixed meal test), and a range of inflammatory markers. The second aim was to test whether and to what 
extent the observed abnormalities resolve following weight loss, thereby verifying the assumption that fat accu-
mulation is their prime cause. For this purpose, in the same subjects we exploited the potency of bariatric surgery 
(Roux-en-Y gastric bypass (RYGB)) to induce major weight loss and a stable reduced body weight 1 year after 
surgery, when the histological and physiological studies were repeated.
Methods
Subjects. We studied 13 morbidly obese patients with T2D and 15 gender-, and BMI-matched non-diabetic 
morbidly obese patients (ND). Diabetes was newly diagnosed in 3 patients, while in the other 10 patients known 
duration was 5.0 ± 1.6 years (range 1–10). Mean HbA1c was 7.2 ± 0.5% (55.0 ± 4.6 mmol/mol) in the whole group 
of the T2D patients, antidiabetic treatment was diet alone in 5 patients, oral hypoglycaemic agents in 8 (met-
formin in 4, metformin plus a sulphonylurea in 3, pioglitazone in 1 patient). Eleven T2D and 8 ND participants 
were restudied 1 year after RYGB and received a repeat biopsy of subcutaneous adipose tissue and muscle. As a 
reference group for the metabolic variables, we used metabolic data from 611 non-diabetic, lean (BMI ≤ 25 kg/m2) 
men and women from the RISC Study13; glycerol turnover measurements were obtained in 8 of them. For com-
parison purposes of tissue analysis, fat biopsies were also available for 9 lean nondiabetic subjects (4 women 
and 5 men, age 53 ± 6 years, BMI = 23.6 ± 0.7 kg/m2) undergoing non-bariatric abdominal surgery; from these, 
subcutaneous fat was available for 6 subjects and visceral fat for 5 subjects. The study was approved by the Ethics 
Committee of the University of Pisa. The nature and purpose of the study were carefully explained to all subjects 
before they provided their written consent to participate to the study. All methods were performed in accordance 
with the relevant guidelines and regulations. Glucose flux and beta-cell function data from a larger group of sur-
gical patients have been previously reported14, 15.
Study design. At the time of study prior to surgery, body weight had been stable for at least six months and 
did not change between screening and study time. Antidiabetic therapy was discontinued one week before the 
metabolic study in the 8 diabetic patients on antihyperglycaemic treatment. Each metabolic study consisted of a 
euglycaemic hyperinsulinaemic clamp combined with the infusion of tracer glycerol14. On a different day at base-
line and follow up, subjects received a mixed meal test (MMT, 75 g of glucose in 150 ml of water, 40 g of parmesan 
cheese, and one 50-g egg; 509 kcal, 16% protein, 28% fat, 56% carbohydrate)15.
Surgical procedure and biopsies. RYGB was performed as described14. During the surgery, a few grams of 
omental (VAT) and subcutaneous (SAT) adipose tissue and of rectus abdominis muscle were excised and imme-
diately fixed in 4% phosphate buffered formaldehyde solution, and sent for morphological evaluation. Likewise, 
adipose tissue samples were also obtained in lean controls during non-bariatric abdominal surgery. In the patients 
that were restudied 1 year after RYGB, percutaneous biopsies of subcutaneous fat and muscle were performed. 
Briefly, participants were instructed not to perform strenuous physical exercise for 48 hours before the biopsy 
procedure. Under local anaesthesia (10 ml carbocaine), tissue specimens were obtained through a small incision 
of the left abdominal mid-quadrant (at the same level of the previous laparoscopic access).
Analytical procedures. Plasma glucose was measured by the glucose oxidase technique (Analox GM-9), 
plasma insulin and C-peptide by electrochemiluminescence (on a COBAS e 411 instrument, Roche, Indianapolis, 
USA). Plasma triacylglycerols and serum high-density lipoprotein (HDL) cholesterol were assayed in duplicate 
by standard spectrophotometric methods on a Synchron Clinical System CX4 (Beckman Instruments, Fullerton, 
USA). Plasma 2H5-glycerol enrichment was measured by gas chromatography/mass spectrometry (GCMS), as 
described previously16.
Data analysis. Whole-body fat-free mass was estimated by electric bioimpedance on a Tanita scale; of note, 
this method has been validated in very obese individuals against the deuterated water technique17. Lipolysis was 
estimated as the glycerol rate of appearance (RaGly, in µmol.min−1), and calculated using steady-state equations 
for the fasting state and Steele’s equations during the clamp, as previously described14. An index of adipose tissue 
insulin resistance (AT-IR) was calculated as the product of RaGly (normalized per kg of fat mass) and fasting 
plasma insulin concentration18.
Insulin-stimulated glucose disposal was expressed per kg of fat-free mass (FFM) (M, µmol.min−1.kgFFM−1); 
insulin sensitivity was indexed as the ratio of M to the steady-state plasma insulin concentrations (M/I, in µmol.
min−1.kgFFM−1.pM−1)14.
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Beta-cell function was quantitated by mathematical modeling of the plasma C-peptide response to the MTT, 
as described19, 20. The test, which allows to obtain an estimate of the principal parameters of beta-cell function 
after a physiological stimulus, is better tolerated than oral glucose postsurgery. The main parameter of the model 
is beta-cell glucose sensitivity ß-GS), which is calculated as the mean slope of the dose-response function (i.e., the 
relationship between insulin secretion rates and plasma glucose concentrations during corresponding times of 
the MMT). The model also yields a measure of the total amount of insulin released over the 5 hours of the meal15.
Tissue analysis. Samples of skeletal muscle were dehydrated in ethanol, postfixed in osmium, and 
paraffin-embedded21. Transverse sections were stained with hematoxylin-eosin and analyzed for the presence of 
lipid droplets in the perivascular space (perivascular lipid), between fibers (interfibrillar lipid), and inside fibers 
(intramyocellular lipid). In each location, lipid content was scored as follows: 0, none; 0.5, just distinguishable, 
with focal distribution; 1, detectable in restricted areas of the parenchyma but in scarce amount; 2, well evident 
in different areas of the parenchyma; and 3, numerous and/or voluminous, generally confluent droplets in diffuse 
areas of the parenchyma. The quantitative assessment was carried out by three authors (A.V., I.S. and G.B.) who 
were blinded to the participant group and metabolic data; the results were tested in repeated measurements of the 
same specimen and were found to be reproducible within 10%. This method was also used in a previous paper21.
Light microscopy and immunohistochemistry of adipose tissue. For light microscopy and immu-
nohistochemistry, tissue fragments were paraffin embedded and sectioned for morphometric evaluations; 
hematoxylin/eosin staining was used to assess morphology. Other selected sections were stained by immuno-
histochemistry (with the use of the Mac-2 and CD68 antibody to reveal the presence of macrophages and CLS) 
using a Vectastain ABC Kit peroxidase labeled (Vector Laboratories) and enzyme localization by DAB substrate22.
Electron microscopy. Subcutaneous and omental fat samples obtained during surgery and subcutaneous 
fat from biopsies were also analyzed by transmission electron microscopy. Small fragments of tissue were fixed 
in 2% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, for 4 hours, postfixed in 1% 
osmium tetroxide, and embedded in an Epon-Araldite mixture. Semi-thin sections (2 µ) were stained with tolui-
dine blue, and thin sections were obtained with an MT-X ultratome (RMC, Tucson, AZ), stained with lead citrate. 
At least three thin section for each patient were examined in a blinded way with a CM10 transmission electron 
microscope (Philips, Eindhoven, The Netherlands)22. Morphometric evaluations were performed using an image 
analysis software (Lucia IMAGE version 4.82, Laboratory Imaging). Five patients in each condition were exam-
ined. Ten electron micrographs of each adipose depot of each patient were taken to calculate cytoplasmic and 
basal membrane thickness (expressed in µm), size (µm2), and density (number of mitochondria in 10 µm2) of 
mitochondria.
Morphometry. Tissue sections was observed with a Nikon Eclipse E800 light microscope using a 20 objec-
tive, and digital images were captured with a DXM 1200 camera. Crown-like structure (CLS) density (CLS per 
104 adipocytes), adipocyte surface area, and adipocyte volume was determined by the Nikon Lucia IMAGE (v. 
4.61) image analysis software22.
Statistical analysis. Data are given as mean ± SEM or, if non-normally distributed, as median and [inter-
quartile range]. The Mann-Whitney U test was used to compare group values, paired group values were analyzed 
by Wilcoxon sign rank test. Treatment-induced changes were tested by repeated-measure ANOVA, with group 
(ND or T2D) as a fixed effect; for this analysis, non-normally distributed variables were log-transformed. Simple 
associations were tested by calculating the Spearman rank correlation coefficient (ρ). Statistical analyses were 
carried out using Stat View 5.0 software; a p value ≤ 0.05 was considered significant.
Results
Baseline. T2D patients were older than ND subjects but had similar body weight and composition. Both T2D 
and ND subjects were markedly insulin resistant (M/I) as compared with historical lean controls13 (Table 1). T2D 
patients had fasting hyperglycaemia, lower total insulin secretion rate, and profoundly impaired beta-cell glucose 
sensitivity (ß-GS) compared with ND (Table 1). Neither adiponectin nor cytokines (MCP-1, IL-6, and TNFα) 
differed between the two groups. All metabolic parameters of the surgical patients were significantly altered in 
comparison to the group of historical controls, with the exception of ß-GS which was preserved in non-diabetic 
obese patients.
Light microscopy. Fat accumulation in rectus abdominis muscle was similar between T2D and ND patients 
in the perivascular and interfibrillar areas (Table 2). In contrast, intramyocellular fat was more abundant in T2D 
than ND patients (Fig. 1A). In SAT, the adipocyte area was similar in T2D and ND patients (Fig. 2A), and larger 
than in the lean controls (adipocyte area SAT in lean controls group 5349 [2948] µm2, p < 0.04 vs ND and p < 0.01 
T2D). In VAT, the adipocyte area was smaller than in SAT, was larger in T2D than ND patients (Fig. 2A) and 
expanded as compared to lean controls (adipocyte area VAT of lean controls group 2575 [807]µm2, p < 0.04 vs ND 
and p < 0.01 T2D). In both depots, CLS density was higher in T2D than ND patients (Fig. 2B).
In SAT of two T2D patients we found structures never described previously. They had the general 
structural characteristics of CLS (i.e., roundish, perilipin-negative central lipid droplet) (Fig. 3A) with 
CD68-immunoreactive macrophages and giant CD68-immunoreactive multinucleated cells surrounding the 
lipid core (Fig. 3B). Their size was ~10-fold that of the largest CLS and largest adipocyte ever described (Fig. 3A 
inset). We named these structures Cyst-Like-Structures (CyLS). In these 2 individuals, the size of VAT and SAT 
adipocytes exceeded by ~30% that of the average adipocyte area of the other 26 subjects in the current series.
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Electron microscopy. VAT in ND patients. In VAT of ND subjects, adipocytes displayed a thin rim 
(ND = 0.48 [0.16] µm vs Ct = 0.80 [0.27] µm, p = 0.01, Fig. 4A), few small mitochondria and frequent lipofus-
cins; abundant collagen fibrils were observed in close association with the basal membrane and in the inter-
stitium (Fig. 4B). Rare cytoplasmic crystals, and dilated rough endoplasmic reticulum (RER) were also found. 
Degenerating adipocytes (in line with the presence of perilipin-negative adipocyte-like cells by immunohisto-
chemistry) and extrusion of lipid droplets in the interstitium were frequently found. Basal membranes were often 
thickened and highly irregular. Mast cells were found in close proximity of adipocytes and sometimes surround-
ing intact adipocytes to form clustering arrays.
VAT in T2D patients. In VAT of T2D patients, additional changes were calcium-like crystals in the cytoplasm of 
some cells (Fig. 4C), macrophages in close proximity to adipocytes (also detected by CD68 immunohistochem-
istry), and neutrophils in the interstitium and blood capillaries, likely expression of parenchymal inflammation.
ND T2D p* Ctrls
Number (F/M) 15 (14/1) 13 (9/4) ns 611 (405/206)
Age (years) 41 ± 3 50 ± 2 0.01 43 ± 1
BMI (kg.m−2) 51.0 ± 1.6 50.0 ± 2.2 ns 22.4 ± 1.8°
FM (%) 52 ± 1 47 ± 2 ns 24 ± 8°
FM (kg) 72 ± 4 63 ± 5 ns 16 ± 5°
FFM (kg) 67 ± 3 71 ± 5 ns 49 ± 9°
Waist circumference (cm) 133 ± 3 141 ± 7 ns 78 ± 9°
Fasting glucose (mmol/L) 5.5 ± 0.1 9.1 ± 0.8 <0.0001 4.9 ± 0.5°
Fasting insulin (pmol/L) 138 [72] 137 [115] ns 23 [16]°
Plasma NEFA (mmol/L) 0.58 [0.25] 0.67 [0.14] ns 0.51 [0.26]°
Total cholesterol (mmol/L) 4.5 ± 0.2 4.6 ± 0.3 ns 4.8 ± 0.9
Triacylglycerols (mmol/L) 1.2 [0.5] 1.3 [0.7] ns 0.8 [0.5]°
HDL-cholesterol (mmol/L) 1.2 ± 0.1 1.1 ± 0.1 ns 1.6 ± 0.4°
Adiponectin (ng/ml) 6.1 ± 0.7 6.7 ± 1.0 ns 9.5 ± 4.1°
MCP-1 (pg/ml) 235 [154] 265 [120] ns nd
IL-6 (pg/ml) 3.66 [2.19] 5.77 [3.54] ns 0.86 [1.6]°
TNFa (pg/ml) 1.45 [0.61] 1.17 [0.46] ns 0.75 [0.31]°
M/I (nmol.min−1.kgFFM−1.pM-1) 31 [22] 25 [31] ns 154 [83]°
RaGly (µmol.min−1) 354 [92] 349 [91] ns 113 [86]°
AT-IR (mmol.min−1.kgFM−1.pM) 0.54 [0.63] 0.83 [0.68] ns 0.30 [0.16]°
Mean Glucose (mmol/L) 6.0 ± 0.2 9.8 ± 1.0 <0.0001 6.3 ± 0.1°
ß-GS (pmol.min−1.m−2.mM−1) 128 [42] 21 [24] <0.0001 125 [86]°
Total insulin output (nmol.m−2) 97 [41] 50 [45] 0.004 37 [15]°
Fasting ISR (pmol.min−1.m−2) 144[103] 99 [100] ns 59 [26]°
Table 1. Baseline anthropometric and metabolic parameters in nondiabetic (ND) and diabetic (T2D) surgical 
patients and in non-obese control subjects (Ctrls)§. §Entries are mean ± SEM or median [interquartile range]; 
BMI = body mass index; FM = fat mass; NEFA = nonesterified fatty acids; MCP-1 = monocyte chemoattractant 
protein; IL-6 = interleukin-6; TNFα = tumor necrosis factor-α; M/I = insulin-mediated glucose disposal rate; 
RaGly = glycerol rate of appearance; AT-IR = adipose tissue insulin resistance index; Mean Glucose = calculated 
from the glucose AUC during MTT; ß-GS = beta-cell glucose sensitivity; ISR = insulin secretion rate; nd = not 
determined. *T2D vs ND by Mann Whitney test. °p ≤ 0.05 for the difference between controls (Ctrls) and the 
combined ND and T2D group.
Baseline Effect of surgery
ND T2D ND pre ND post T2D pre T2D post
Number (F/M) 15 (14/1) 13 (9/4) 8 (7/1) 8 (7/1) 11 (7/4) 11 (7/4)
Perivascular 
muscle fat (units) 1.25 [1.75] 2.00 [2.50] 2.25 [1.50] 1.50 [1.88] 2.00 [2.25] 1.00 [0.75]
Interfibrillar 
muscle fat (units) 1.50 [1.44] 2.00 [1.00] 1.50 [1.00] 0.75 [0.94] 2.00 [1.00] 0.75 [0.88]*
Intramyocellular 
fat (units) 0.00 [0.44] 1.00 [0.50] ° 0.12 [0.50] 0.00 [0.00] 1.00 [0.50] 0.00 [0.25]*
Table 2. Changes in muscle histology (semi-quantitative analyses)§. §entries are median [interquartile range]. 
°p ≤ 0.01 T2D vs ND by Mann Whitney test. *p ≤ 0.05 for the changes at 1 year vs baseline by Wilcoxon sign 
rank test.
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SAT in ND patients. In SAT of ND patients, adipocytes had very thin cytoplasm (0.37 [0.45] µm, i.e., about 
25% thinner than that of VAT adipocytes in line with their larger size), with very small (ND = 0.06 [0.01] µm2 vs 
Ct = 0.14 [0.06] µm2, p = 0.01), rare (ND = 1.08 [0.57]/10 µm2 vs Ct = 4.22 [2.09]/10 µm−2, p = 0.01) mitochon-
dria. Organelles were very rarely visible, and often degenerative signs were observed. Basal membranes were 
often thickened (ND = 0.118 [0.018] µm vs Ct = 0.073[0.009] µm, p = 0.01) and sometimes duplicated. In the 
interstitium, free lipid droplets, and macrophages could be found, and fibrosis was less pronouced than in VAT.
SAT in T2D patients. In SAT of T2D patients, rare crystals and glycogen accumulation were observed in the 
cytoplasm of some adipocytes. There were frequent degenerating adipocytes (Fig. 4D,E), and intravascular 
Figure 1. Skeletal muscle from a diabetic (T2D) patient pre (A) and post (B) bariatric surgery. A reduction of 
intermyocellular fat is evident (red dots).
Figure 2. Mean adipocyte area (A) and crown-like structure density (CLS number/104 adipocytes, (B)) from 
lean controls (Ctrls), ND and T2D patient biopses of visceral (VAT) and subcutaneous (SAT) depots before 
surgery (Baseline). In C and D, the same parameters have been shown in subcutaneous adipose tissues from 
ND and T2D patient biopsies before (Baseline) and post-surgery (1 year after surgery). In (A and B) (#)p < 0.05 
by Mann Whitney U test for comparison of ND and T2D vs Ctrls; (§)p < 0.05 by Mann Whitney U test for 
comparison of T2D vs ND; and (*)p < 0.05 by Wilcoxon sign rank test to compare VAT vs SAT in each group. In 
C and D (*)p < 0.05 for the changes at 1 year vs baseline by Wilcoxon sign rank test.
www.nature.com/scientificreports/
6SCIENtIfIC REpoRTS | 7: 9007  | DOI:10.1038/s41598-017-08444-6
parenchymal inflammation, with neutrophils, macrophages, and free lipids in the interstitium. Inflammatory cells 
and fibrosis as well as irregular basal membranes (T2D = 0.111 [0.025] µm vs Ct = 0.073 [0.009] µm, p = 0.01) 
were more pronounced than in lean patients.
After surgery. One year after surgery, patients in both groups had lost an average 33% of their initial body 
weight and most metabolic parameters had improved significantly (Supplemental Table S1). Three patients 
experienced dumping like symptoms (nausea, sweating, tachycardia) after meal ingestion. In the T2D group, all 
patients were off antidiabetic treatment, and mean HbA1c was 5.5 ± 0.2% (36.6 ± 1.7 mmol/mol) (p = 0.01 vs base-
line). Adiponectin levels were increased and IL-6 decreased, whereas TNFα was unchanged. Insulin sensitivity 
(M/I) was significantly improved compared to baseline in both groups; in contrast, beta-cell glucose sensitivity 
was slightly reduced in ND and much improved – though not normalized – in T2D.
Light microscopy. In rectus abdominis, fat deposition tended to be reduced in all locations, perivascular, 
interfibrillar and intramyocellular in both ND and T2D (Table 2). In particular, intramyocellular fat had virtually 
disappeared in both ND and T2D patients (Fig. 1B). In SAT, adipocyte area was markedly reduced in both groups, 
and was no longer expanded as compared to lean controls (Fig. 2C). CLS density in SAT was reduced in both 
groups (Fig. 2D). Sparse (not organized in CLS) CD68-immunoreactive macrophages were still present in the 
tissue of most patients, especially of T2D patients (Fig. 5).
Electron microscopy. In SAT of both ND (n = 6) and T2D (n = 8) individuals, adipocytes showed a thicker 
cytoplasmic rim (before vs after surgery: ND = 0.37 [0.45] vs 0.58 [0.26] µm, p = ns; T2D = 0.44 [0.27] vs 0.58 
[0.10] µm, p = 0.04) containing more mitochondria (before vs after surgery: ND = 1.08 [0.57]/10 µm2 vs 1.98 
[0.92]/10 µm2, p = 0.04; T2D = 1.54 [1.11]/10 µm2 vs 3.11 [1.99]/10 µm2, p = ns) (Fig. 4F). Dilated RER, glyco-
gen accumulation, cholesterol-like cristals and thickened basal membrane (before vs after surgery: ND = 0.118 
[0.018] µm vs 0.123 [0.011] µm, p = ns; T2D = 0.111 [0.025] vs 0.103 [0.026] µm, p = ns) were still present only in 
some cells of both ND and T2D patients (Fig. 4G).
Correlations. Most of the baseline measures were intercorrelated both before and after surgery; the pattern of 
statistically significant associations is summarized in Table 3. In brief, a higher BMI or waist circumference was 
positively associated with larger adipocytes and more numerous CLS in both SAT and VAT, more muscle fat, and 
raised circulating IL-6 concentrations (waist p = 0.0008, r2 = 0.35; BMI p = 0.0001, r2 = 0.30). In turn, expansion 
of SAT depots was associated with lower adiponectin levels (r2 = 0.32), and with muscle (M/I, r2 = 0.51) and 
adipose tissue insulin sensitivity (AT-IR, r2 = 0.34). Muscle and adipose tissue insulin sensitivity was related to 
perivascular fat (M/I r2 = 0.12; AT-IR r2 = 0.26) and interfibrillar muscle fat (M/I r2 = 0.13). Increased VAT adi-
pocyte area was related to more CLS both in VAT (p = 0.005, r2 = 0.30) and in SAT (p = 0.008, r2 = 0.35) and more 
intramyocellular fat (r2 = 0.36). Furthermore in baseline condition, ß-GS was inversely related to VAT adipocyte 
area (r2 = 0.34) and VAT CLS density (p = 0.02, r2 = 0.25) and to intramyocellular fat (p = 0.006, r2 = 0.37). These 
three variables explained 64% of the variation of ß-GS (p = 0.004, r2 = 0.64) before surgery. All the described 
relationships were mantained after adjusting for age and sex in a multivariate analysis.
Figure 3. Light microscopy of subcutaneous adipose tissue (SAT) of an obese patient with type 2 diabetes. 
Immunohistochemistry for CD68. (A) Cyst-Like-Structure (Cys-LS) formed by CD68 immunoreactive 
macrophages and multinucleated giant cells (MGC) surrounding fat, amidst hypertrophic adipocytes. Note the 
giant size of Cys-LS in comparison with hypertrophic adipocytes and the largest CLS found in the same patient. 
(B) Magnification of the inset in A.
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Figure 4. In A,B and C electron microscopy of visceral fat. (A) Visceral fat of a lean control subject. (B) 
Visceral fat of an obese non-diabetic (ND) patient. Note the different thickness of the cytoplasmic rim, small 
and rare mitochondria and abundant collagen (enlarged in the inset) in the obese patient. A mast cell is close 
to the adipocyte of the obese patient. (C) Visceral fat of a T2D patient. The cytoplasm of two degenerating 
adipocytes is visible. Note the presence of calcium-like crystals in one adipocyte. In D and C electron 
microscopy of subcutaneous adipose tissue (SAT) of two obese patients with type 2 diabetes. (D) Degenerative 
signs (D) and a close-by macrophage in the interstitium (M). (E) The cytoplasm of two degenerating adipocytes 
is visible. The lipid droplet (L) and basal membrane (BM) are still distinguishable, but the cytoplasm and 
organelles are not recognizable and are mixed with a dark material that seems to overlay the basal membrane 
and occupy the interstitium in the form of irregular dots (D) with the same electrondensity of the degenerating 
cytoplasm. Overall, the fine morphology is compatible with that of degenerating adipocytes (Cinti S et al.6. In 
F and G electron microscopy of subcutaneous adipose tissue (SAT) of two obese patients with type 2 diabetes 
post-surgery. (F) The cytoplasmic rim is thicker than pre-surgery (cfr, E) and clusters of mitochondria (m) are 
visible. BM = basal membrane, COL = collagen fibrils. (G) In this adipocyte (left), signs of stress were present: 
dilated rough endoplasmic reticulum (RER), cholesterol crystals (C), and thick basal membrane (BM). L = lipid 
droplets, m = mitochondria, BM = basal membrane, COL = collagen fibrils. 196 × 297 mm (150 × 150 DPI).
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Discussion
The main findings of this study are: (a) the alterations of fat and skeletal muscle morphology of the obese correlate 
well with the insulin resistance and associated metabolic abnormalities that characterize this condition; (b) both 
VAT and SAT adipocytes exhibit more marked histologic abnormalities in T2D than ND subjects; (c) VAT his-
tology is associated with beta-cell dysfunction in T2D; and (d) following major weight loss, tissue histology and 
metabolic function improve consensually; however, in T2D incomplete recovery of beta-cell function suggests the 
presence of an inherent secretory defect. These findings require specification.
Firstly, the baseline data obtained before surgery recapitulate the key metabolic findings of obesity and 
T2D. Thus, our patients showed insulin resistance of glucose metabolism and lipolysis, hyperinsulinemia and 
insulin hypersecretion, dyslipidemia, reduced levels of adiponectin, and raised circulating levels of markers of 
inflammation. In the T2D patients, beta-cell glucose sensitivity was severely impaired in comparison with the 
weight-matched ND subjects. Secondly, adipocyte size was clearly expanded in both subcutaneous and visceral 
depots, with evidence of cell stress, degeneration and necrosis, in line with recent observations in murine obese 
adipocytes23. The significant association of adipocyte size with increased lipolysis and depressed insulin action 
(ρ = 0.73 for both, p < 0.0001) confirms the pathogenic potential of adipocyte hypertrophy in humans24–26. 
This change in adipocyte phenotype likely led to reduced release of adiponectin and enhanced release of IL-627. 
Macrophage infiltration and crown-like structures were more abundant in VAT than SAT despite the fact that 
VAT cells were smaller than SAT cells. This finding extend to humans the observation – made in genetically obese 
mice7 – that the “critical death size” is lower in VAT adipocytes9, and that hypoxia induces adipose tissue remod-
eling28. Thirdly, VAT area and morphological alterations (CLS and inflammatory/necrotic changes) prevailed in 
T2D as compared to ND obese patients and correlated with beta-cell dysfunction. The latter result coupled with 
the excess fat infiltration of skeletal muscle indicates that the inherent beta-cell defect of T2D – as seen in lean 
T2D patients – is worsened by more severe VAT inflammation.
Of note is that cyst-like structures (in SAT from 2 T2D patients out of 26 examined) have not been previosuly 
described in fat tissues of lean or obese mice or in humans. Their architecture suggests that these structures may 
originate from extremely large, necrotic adipocytes23. It is noteworthy that the adipocytes in these two patients 
were particularly enlarged, exceeding the size of other obese patients by about 30%. In such cells, the very thin 
cytoplasm (thinnest cytoplasmic rims were about 1/10 of that of adipocytes of control patients) can rupture, 
thereby expelling lipid droplets into the interstitium. The resulting coalesced “oil” vacuole acts as a foreign body 
and is therefore surrounded by macrophages and giant multinucleated cells, in a manner similar to the mecha-
nism hypothesized for CLS formation8 (Supplemental Figure S1). In line with this hypothesis, oil injections into 
the subcutaneus fat of mice give rise to similar structures (Cinti et al., personal observations).
Surgery provided a robust test for the cause-effect value of the histological/metabolic relationships. With 
major weight loss, all of the metabolic abnormalities improved despite the fact that in most patients BMI 
remained in the obese range. Thus, hyperinsulinemia and fasting insulin hypersecretion abated, dyslipidemia 
reversed, and the circulating concentrations of MCP-1 and IL-6 (but not TNFα) decreased. Insulin sensitivity 
of glucose metabolism and lipolysis improved in rough proportion to the amount of weight lost but remained 
subnormal in both ND and T2D subjects. In parallel with these metabolic changes, tissue histology was drasti-
cally altered29, 30. In subcutaneous fat, adipocyte size was reduced by ~50%, and CLS became rare. These results 
Figure 5. Light microscopy of subcutaneous adipose tissue (SAT) of an obese patient with type 2 diabetes post-
surgery. Immunohistochemistry for CD68. Several CD68 immunoreactive macrophages (brown) are present 
among unstained adipocytes and capillaries (CAP).
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in postsurgery patients are consistent with recent data showing that adipose tissue morphology and insulin sen-
sitivity in humans are closely linked31–33. Signs of acute intravascular inflammation almost disappeared together 
with a general restoration of adipocyte morphology. Certain stress-related changes persisted, however. Thus, 
accumulation of glycogen and collagen fibrils, dilated RER, crystals, alterations of basal membrane, and signs of 
degeneration in adipocytes, and sparse macrophages (mainly in T2D patients) were still present in SAT, possibly 
accounting for the persistence of circulating TNFα levels.
Collectively, the postsurgery results support the interpretation that obesity itself was a partially reversible 
cause of both the histopathology and the metabolic derangements of our patients. A circumstance takes excep-
tion to this conclusion, namely, that baseline beta-cell function was within the normal range in the ND subjects 
despite the fat and muscle alterations and, on the other hand, in T2D subjects beta-cell function was not fully 
restored after weight loss despite the almost recovery of SAT and muscle morphological alterations29, 30. The lack 
of VAT tissue after weight reduction in ours patients represents a limitation of our study as we cannot gauge the 
contribution of residual inflammatory/necrotic changes in VAT to beta-cell dysfunction. However, it is notewor-
thy that, in the baseline dataset VAT adipocyte area is reciprocally associated with beta-cell function (Table 3), 
and the association persists after adjusting for sex, SAT adipocyte area and intramyocellular fat (p = 0.002). On 
these grounds, it may be hypothesized that abnormalities in VAT may be more specifically linked with beta-cell 
dysfunction, possibly through residual inflammation as signaled by the unchanged levels of TNF-a and MCP-1 
(Supplemental Table S1).
It is pertinent to recall that in non-diabetic patients omentectomy in patients undergoing bariatric surgery 
did not enhance the effect of bariatric surgery on insulin sensitivity but was associated with improved insulin 
secretion34. Therefore, the current results are compatible with the concept that diabetes is a condition of intrin-
sic beta-cell incompetence, which fat/muscle pathology may aggravate by propagation of inflammatory reac-
tions35–37. The complex cross-talk between muscle38 and/or fat39, 40 and the islets of Langerhans is only beginning 
to be unraveled. The crosstalk between adipose tissue and the endocrine pancreas is also mediated by two circu-
lating adipokines, namely adiponectin and adipsin. These factors, which are reduced in obesity models, may exert 
a direct action on beta-cell function and/or insulin sensitivity41–43. In line with this possibility, in our postsurgery 
patients the increased adiponectin levels may have contributed to the improvement of glucose metabolism.
The finding that neither body weight nor insulin sensitivity were restored to normal one year after surgery in 
either of our two study groups is the rule for severely obese subjects14; as a consequence, proof that the sequence 
starting with weight gain can be fully reversed is lacking.
In summary, in morbid obesity subcutaneous fat morphological alterations – adipocyte hypertrophy, degen-
erative changes and necrosis, macrophage infiltration and formation of crown-like/cyst-like structures – and 
muscle fat accumulation correlate with insulin resistance of glucose utilization and lipolysis and with raised 
plasma inflammatory biomarkers. Abnormalities of VAT, more than SAT, cellular changes and intramyocellu-
lar fat accumulation are related to impaired beta-cell function. Following surgery-induced weight loss, most of 
the subcutaneous fat and muscle changes resolve and metabolic functions improve. In the face of only subtle, 












r p r p r p r p r p r p r p r p
Adipocyte area SAT 0.76 <0.0001 ns — — 0.60 <0.0001 ns 0.54 0.0001 0.57 0.0006 −0.36 0.01
CLS SAT 0.59 0.008 0.61 0.006 0.60 <0.0001 — — ns ns 0.39 0.03 ns
Perivasc. muscle fat ns 0.47 0.04 ns ns — — 0.43 0.007 ns ns
Interfibrill. muscle fat ns ns 0.54 0.001 ns 0.43 0.007 — — 0.50 0.003 ns
Intramyocellular fat 0.60 0.005 ns 0.57 0.0006 0.39 0.03 ns 0.50 0.003 — — ns
BMI ns ns 0.89 <0.0001 0.50 0.001 ns 0.45 0.004 0.42 0.008 −0.61 <0.0001
Waist circumference 0.59 0.01 0.54 0.03 0.86 <0.0001 0.61 0.001 0.44 0.03 0.44 0.03 ns ns −0.41 0.004
Fasting glucose ns 0.60 0.002 0.44 0.003 0.36 0.04 0.36 0.04 ns 0.35 0.04 ns
Fasting insulin ns ns 0.70 <0.0001 0.52 0.0008 0.46 0.004 ns 0.36 0.03 −0.20 0.049
HbA1c ns 0.65 0.02 0.54 0.02 0.57 0.02 ns ns ns ns
Mean Glucose 0.43 0.04 0.53 0.007 0.40 0.009 0.57 0.0003 ns 0.41 0.01 ns ns
Adiponectin ns ns −0.56 0.0002 −0.39 0.02 ns ns ns 0.54 0.0004
MCP1 ns ns 0.35 0.03 0.37 0.03 ns ns 0.40 0.02 ns
IL-6 ns ns 0.50 0.001 ns 0.41 0.02 ns 0.40 0.02 ns
M ns −0.42 0.03 −0.62 <0.0001 −0.42 0.009 −0.35 0.03 ns ns ns
M/I ns ns −0.72 <0.0001 −0.43 0.008 −0.35 0.03 −0.36 0.03 ns 0.38 0.004
AT-IR ns ns 0.58 <0.0001 0.35 0.04 0.51 0.001 ns ns ns
ß-GS −0.58 0.004 −0.50 0.02 ns −0.43 0.01 ns ns −0.48 0.004 ns
Fasting ISR ns ns 0.54 0.0002 0.45 0.006 0.41 0.002 ns ns ns
Table 3. Correlation among clinical, histological, and metabolic parameters in the combined ND and T2D 
groups.
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residual pathological changes in adipose tissue, however, insulin sensitivity remains subnormal and, in T2D 
patients, beta-cell function is not fully restored, suggesting persistence of a degree of visceral fat abnormalities 
that deserves further study.
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